Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10591272 | Bioorganic & Medicinal Chemistry Letters | 2013 | 5 Pages |
Abstract
Introducing a sulfamide moiety to our coumarin derivatives afforded enhanced Raf/MEK inhibitory activity concomitantly with an acceptable PK profile. Novel sulfamide 17 showed potent HCT116 cell growth inhibition (IC50Â =Â 8Â nM) and good PK profile (bioavailability of 51% in mouse), resulting in high in vivo antitumor efficacy in the HCT116 xenograft (ED50Â =Â 4.8Â mg/kg). We confirmed the sulfamide moiety showed no negative impact on tests run on the compound to evaluate DMPK (PK profiles in three animal species, CYP inhibition and CYP induction) and the safety profile (hERG and AMES tests). Sulfamide 17 had favorable properties that warranted further preclinical assessment
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Toshihiro Aoki, Ikumi Hyohdoh, Noriyuki Furuichi, Sawako Ozawa, Fumio Watanabe, Masayuki Matsushita, Masahiro Sakaitani, Kazutomo Ori, Kenji Takanashi, Naoki Harada, Yasushi Tomii, Mitsuyasu Tabo, Kiyoshi Yoshinari, Yuko Aoki, Nobuo Shimma,